Cigna Healthcare
Cigna Healthcare is the health insurance business of The Cigna Group, a global health services company that also offers pharmacy benefits through Express Scripts (Evernorth Health Services). The Cigna Group reports about 182 million customer relationships worldwide across commercial and international markets, having sold its Medicare businesses to HCSC in 2025.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-27.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
CIGNA was formed in March 1982 from the merger of Connecticut General and INA, a diversified insurer spanning life, property-casualty and employee benefits. Through the 1990s employers moved workers into managed care with selective networks, and Cigna narrowed its focus by selling most of its individual life and annuity business to Lincoln National in 1997. Algorithmic claims review and PBM ownership were still decades away.
The July 1999 sale of its property-casualty business to ACE for $3.45 billion left Cigna a focused health and benefits company. A botched January 2002 systems migration disrupted service for millions of members and cost it 6% of its medical membership, and in 2003 it settled class actions by some 700,000 physicians over claims-payment practices. The 2007 transplant denial for Nataline Sarkisyan and former communications chief Wendell Potter's 2009 Senate testimony made Cigna a symbol of insurer denials.
Under CEO David Cordani, Cigna built the PxDx review system around 2010, letting medical directors deny mismatched claims in bulk, and bought HealthSpring in January 2012 to enter Medicare Advantage, where in-home assessment and chart-review programs later drew a $172 million False Claims Act settlement. CMS suspended Cigna's Medicare Advantage and Part D enrollment in January 2016 over appeals, grievance and formulary failures. Anthem's $54 billion bid for Cigna was blocked on antitrust grounds in 2017.
Closing the $67 billion Express Scripts deal in December 2018 made Cigna an insurer, PBM, specialty pharmacy (Accredo) and utilization manager (eviCore) in one company, absorbing a PBM that had merged with Medco in 2012 and whose Accredo unit paid $60 million in 2015 to settle a kickback case. Express Scripts' 2019 reimbursement pact with Prime, later attacked as price fixing, cut pharmacy payments, while copay-maximizer programs and rebate arrangements added margin. Inside the insurer, PxDx denied over 300,000 claims in two months of 2022, medical directors were pushed on productivity dashboards, and Cordani's 2021 realized pay topped $91 million.
ProPublica's March 2023 PxDx exposé brought a House inquiry and class actions, and later that year Cigna paid $172 million to settle Medicare Advantage upcoding claims. After Humana talks collapsed it added $10 billion of buyback authority and repurchased about $7 billion in 2024. The FTC sued Express Scripts over insulin rebating in September 2024 as Express Scripts sued the FTC; ProPublica exposed eviCore's denial 'dial'; Cigna sold its Medicare business in March 2025 as Michigan sued over PBM price fixing.
Express Scripts' February 2026 settlement with the FTC committed it to net-price cost sharing, delinked fees and cost-plus pharmacy pay from 2027, alongside Cigna's own rebate-free Signature model. Cigna cut about 2,000 jobs, handed the CEO role to Brian Evanko in July, announced an exit from the ACA exchanges and a review of eviCore, and trimmed prior-authorization volume, while Maryland fined it over automatic downcoding and Florida and Louisiana joined Michigan in suing Express Scripts.
Alternatives
An integrated insurer-provider: Kaiser's health plan mostly pays its own doctors and hospitals, so it has far less need for the bulk claim-review systems Cigna uses. A compilation of ACA marketplace data put Kaiser's claim denial rate at about 6% against Cigna's 21%, and J.D. Power's 2024 commercial health plan study ranked Kaiser first in California, Maryland, Virginia, the Northwest and the South Atlantic. With Cigna leaving the ACA exchanges after 2026, it is a direct option for individual-market members in its area. The catch: Kaiser operates only in 8 states and D.C., you generally must use its own network, and in 2023 it agreed to a $200 million settlement, including a $50 million fine, over delays in mental health care in California.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (70 events)
CIGNA formed from CG-INA merger
Connecticut General Corporation and INA Corporation merged to create CIGNA Corporation, combining CG's strength in life insurance and employee benefits with INA's property-casualty expertise. All approvals were secured by March 31, 1982, creating one of the largest publicly owned insurance and financial services companies in the United States, with joint CEOs Robert Kilpatrick of CG and Ralph Saul of INA.
Managed care enrollment surge restricts patient provider choice
Between 1990 and 1995, HMO enrollment in the U.S. grew from 36.5 million to 58.2 million, and by 1995 the majority of Americans with employer-based insurance were in some form of managed care. Plans relied on selective provider networks and negotiated rates, and many employers simply replaced traditional indemnity coverage with managed care options, sometimes offering only a single plan. Insurers including Cigna built managed care businesses on referral requirements and network restrictions.
Supreme Court limits ERISA preemption in Travelers decision
In New York State Conference of Blue Cross & Blue Shield v. Travelers Insurance Co., the Supreme Court curtailed ERISA's preemption reach, concluding that New York's hospital rate surcharges were not preempted. While nominally a setback for insurers, the ERISA framework continued to shield health plans like Cigna from most state-level consumer protection lawsuits throughout the 1990s, as courts generally upheld preemption for coverage denial claims.
Cigna sells life insurance operations to Lincoln National
Cigna divested the majority of its individual life insurance and annuity operations to Lincoln National Corporation, signaling a strategic pivot toward health insurance and managed care as the core business. This narrowing of focus concentrated Cigna's revenue streams on the higher-margin, more extractive health insurance segment.
Cigna sells property-casualty business to ACE for $3.45 billion
ACE Limited completed its acquisition of CIGNA's domestic and international property and casualty businesses, including run-off operations, for $3.45 billion in cash on July 2, 1999. Together with the 1997 sale of individual life and annuity operations, the divestiture left Cigna concentrated on health care and employee benefits.
Botched systems migration disrupts service for Cigna HealthCare members
In January 2002 Cigna HealthCare moved 3.5 million members from 15 legacy systems to two new platforms as part of a $1 billion IT overhaul, after cutting customer service staff in anticipation of efficiency gains. Service glitches followed, and the insurer's health care membership fell from 13.3 million at the end of 2001 to 12.5 million by January 2003, a loss of about 6% of its members in 2002.
Cigna settles physician class actions over claims-payment practices
Cigna HealthCare announced a settlement with some 700,000 physicians in class actions over the claims-payment practices of managed care companies, including Shane v. Humana. It agreed to change business practices, pay interest on documented claims not paid on time, appoint an external reviewer for billing disputes, fund a $30 million settlement pool and a $15 million foundation, and pay up to $55 million in legal fees.
Supreme Court upholds ERISA preemption for Cigna coverage denials
The U.S. Supreme Court ruled in Aetna Health Inc. v. Davila that state-law causes of action brought under the Texas Health Care Liability Act involving coverage decisions by Cigna Healthcare of Texas and Aetna were preempted by ERISA. The ruling reinforced that patients harmed by coverage denials from employer-sponsored plans could not sue in state court for damages, limiting accountability for insurer decision-making.
Cigna reverses transplant denial for Nataline Sarkisyan hours before her death
Cigna refused to pay for a liver transplant for 17-year-old leukemia patient Nataline Sarkisyan, calling it experimental, despite an appeal from four UCLA doctors. It reversed course in December 2007 while about 150 nurses and community members rallied outside its Glendale office, but she died hours after approval. Her family sued Cigna in December 2008.
Former Cigna communications chief Wendell Potter testifies against insurers
Wendell Potter, who had headed corporate communications at Cigna, told the Senate Commerce Committee that during 20 years in the industry he saw insurers confuse customers and drop sick policyholders to satisfy Wall Street investors, and described industry PR and lobbying campaigns aimed at shaping health reform.
CEO Hanway retires with $110.9 million package
Outgoing CEO H. Edward Hanway received a retirement package totaling $110.9 million, including $18.8 million in 2009 compensation plus pension, deferred compensation, and stock options, according to Cigna's March 2010 SEC filing. The disclosure came as the national debate over healthcare reform was at its peak, with Cigna's trade group AHIP lobbying heavily against reform legislation.
PxDx claim review system developed at Cigna
Cigna developed the PxDx (procedure-to-diagnosis) automated claim review system after bringing in Dr. Alan Muney in 2010. The system matched approved procedures to specific diagnoses and automatically flagged mismatches for denial. Medical directors could then reject flagged claims in bulk without opening individual patient files; ProPublica later found that in two months of 2022 Cigna doctors spent an average of 1.2 seconds on each such denial.
Cigna acquires HealthSpring for $3.8 billion
Cigna acquired HealthSpring Inc. for approximately $3.8 billion in cash, adding nearly 340,000 Medicare Advantage members across 11 states and over 800,000 Medicare Part D customers. The acquisition transformed Cigna from a primarily employer-focused insurer into a major Medicare Advantage player, expanding its reach into the senior market with its higher-margin government-reimbursed plans.
Cigna begins Medicare Advantage 360 assessment program
Cigna contracted with vendors to conduct in-home '360 comprehensive assessments' of Medicare Advantage members, ostensibly for health monitoring. The DOJ later alleged these assessments were primarily designed to capture and record lucrative diagnosis codes that would inflate government reimbursement payments from CMS, rather than to improve patient care.
Express Scripts acquires Medco for $29 billion
Express Scripts completed its $29.1 billion acquisition of Medco Health Solutions on April 2, 2012, after the FTC closed its investigation by a 3-1 vote. The combined company served about 135 million people. Before the review, Representatives Henry Waxman, Frank Pallone and Diana DeGette had warned the FTC that the merged PBMs would control one-third of the PBM market and 60% of mail-order drug market share. Dissenting FTC Commissioner Julie Brill called the deal a 'merger to duopoly' between ESI/Medco and CVS Caremark and put the combined firm's share at about 45%, dramatically concentrating PBM market power that Cigna would later absorb.
Cigna settles multistate probe of disability claims handling, books $77M charge
A coordinated examination by the insurance departments of Maine, Massachusetts, Pennsylvania, Connecticut and California into Cigna's long-term disability claims handling ended in an agreement in principle on March 14, 2013 (finalized in May 2013). Cigna agreed to enhanced claims-handling procedures, two years of monitoring, and reassessment of claims denied or closed in the prior two years (three in California), and recorded a $77 million pre-tax charge covering reopened claims, about $925,000 in fines and other costs.
Express Scripts aggressively expands formulary exclusion lists
Express Scripts dropped 48 brand-name drugs from its standard national preferred formulary for 2014, following CVS Caremark's lead. In an interview, Chief Medical Officer Steven Miller explained that the exclusion criteria included therapeutic interchangeability, manufacturers' copay cards and price increases, making the threat of formulary removal a lever for extracting price and rebate concessions from drug manufacturers.
Cigna enters ACA marketplace exchanges
Cigna began offering individual and family health plans on the Affordable Care Act marketplace exchanges in their initial year. While expanding consumer access, the ACA's annual open enrollment windows also institutionalized the once-per-year switching constraint that adds to health insurance lock-in. Cigna initially offered plans in a limited number of states before gradually expanding.
Cigna launches chart review program for Medicare upcoding
From 2014 to 2019, Cigna operated a 'chart review' program that obtained beneficiary medical charts from physicians and submitted additional diagnosis codes to CMS for higher reimbursement payments. The DOJ later alleged that the added diagnoses were often unsubstantiated, constituting a systematic scheme to inflate Medicare Advantage payments.
Express Scripts announces 400 more layoffs after cutting 1,890 jobs in May
Express Scripts said it would lay off 400 people at multiple facilities, including 90 in St. Louis, on top of 1,890 jobs cut system-wide in May 2014, calling the cuts necessary to position the company for growth. A Saint Louis University health care management professor said some of the layoffs likely reflected streamlining after the 2012 Medco acquisition.
Accredo pays $60 million to settle kickback case over Novartis drug Exjade
Express Scripts' specialty pharmacy Accredo agreed to a $60 million settlement of a civil fraud lawsuit brought by the Manhattan U.S. Attorney over a kickback scheme with Novartis involving the iron-chelation drug Exjade. The government alleged Novartis steered patient referrals to Accredo in exchange for Accredo pushing refills, while understating the drug's potentially life-threatening side effects. Accredo paid about $45.1 million to the United States and about $14.9 million to states, and admitted numerous facts about its relationship with Novartis.
Anthem announces $54 billion acquisition of Cigna
Anthem Inc. (now Elevance Health) announced a definitive agreement to acquire Cigna for $103.40 in cash plus 0.5152 Anthem shares per Cigna share, about $188 per share, valuing the deal at $54.2 billion on an enterprise basis. The proposed mega-merger would have combined two of the five largest U.S. health insurers, further concentrating the already highly concentrated commercial insurance market.
CMS suspends Cigna Medicare Advantage and Part D enrollment
The Centers for Medicare & Medicaid Services imposed intermediate sanctions suspending enrollment of and marketing to new customers in all Cigna Medicare Advantage and standalone prescription drug plan contracts, citing deficiencies in Cigna's Parts C and D appeals and grievances, Part D formulary and benefit administration, and compliance program.
Federal judge blocks Anthem-Cigna merger on antitrust grounds
U.S. District Judge Amy Berman Jackson blocked the proposed $54 billion Anthem-Cigna merger, ruling it would substantially reduce competition in the sale of health insurance to national accounts. The DOJ's antitrust division argued the deal violated Section 7 of the Clayton Act. Anthem abandoned the acquisition attempt in May 2017 after an appeals court upheld the ruling.
Cigna announces $67 billion Express Scripts acquisition
Cigna announced a definitive agreement to acquire Express Scripts, the nation's largest pharmacy benefit manager, for approximately $67 billion including $15 billion in assumed debt. The deal created a vertically integrated health services company combining insurance, PBM, specialty pharmacy, and health analytics under one corporate umbrella, raising immediate concerns about self-dealing and anticompetitive steering.
Cigna completes Express Scripts combination
Cigna completed its combination with Express Scripts effective December 20, 2018, bringing the nation's largest PBM, Accredo specialty pharmacy and eviCore utilization management under the same parent as its health plans. The integrated model lets Cigna bundle medical and pharmacy benefits for employers and route members' prescriptions through its own PBM and pharmacies.
Express Scripts and Prime Therapeutics enter pharmacy reimbursement agreement
Express Scripts and Prime Therapeutics signed an agreement for Prime to adopt Express Scripts' lower pharmacy reimbursement rates in exchange for accessing Express Scripts' buying power. The Michigan Attorney General later alleged this arrangement constituted a price-fixing conspiracy that drove independent pharmacies out of business and created pharmacy deserts in Detroit and rural Michigan communities.
Medicare Advantage insurers deny millions of prior authorizations; most appealed denials overturned
KFF analysis of CMS data found Medicare Advantage insurers fully or partially denied 7.4% of prior authorization requests in 2022 and 6.4% (3.2 million) in 2023, up from 2019 in both share and number. Only about 1 in 10 denials was appealed, yet 81.7% of appealed denials from 2019 to 2023 were partially or fully overturned. Cigna had the highest share of denials appealed among major insurers (18.0% in 2023).
Cigna rebrands health services division as Evernorth
Cigna rebranded its growing health services segment, including Express Scripts, specialty pharmacy Accredo, and utilization management firm eviCore, as Evernorth Health Services. The consolidation under a single brand obscured the extent of vertical integration from consumers while streamlining cross-selling across pharmacy, benefit management, and care solutions.
Cigna pressures medical director to review cases faster
In late 2020, medical director Dr. Debby Day was warned by her bosses to work faster or risk being fired, ProPublica and The Capitol Forum later reported. Cigna ranked its medical directors on monthly productivity dashboards with 'handle times' of about four minutes for a prior authorization, and former medical directors described quick 'click and close' denials of nurse-prepared cases. Cigna said its doctors are not allowed to rubber-stamp denials.
CEO Cordani receives over $91 million in total compensation
Cigna CEO David Cordani took home more than $91 million in 2021, the most of any U.S. health insurance executive, according to a STAT analysis of proxy disclosures that counted actual realized gains from exercised and vested stock. Cigna's proxy statement itself reported his 2021 total compensation as $19.9 million, according to Fierce Healthcare. STAT found Cordani had registered $366 million since 2012, with soaring stock prices fueling most of insurer executives' pay.
Express Scripts' copay maximizer program gains traction
Drug Channels' review of Evernorth's 2020 drug trend report found that utilization drove most drug-spending growth while net post-rebate costs rose 0.9%. It highlighted SaveonSP, Express Scripts' copay maximizer partner, which captures manufacturers' copay assistance for plans and was estimated to keep up to 25% of those funds, and noted that reported costs include PBM retail network spreads.
AMA joins class action against Cigna over underpayments via MultiPlan
The American Medical Association, Medical Society of New Jersey, and Washington State Medical Association became plaintiffs in AMA/Stewart v. Cigna in the District of Connecticut, alleging Cigna failed to pay out-of-network claims at MultiPlan contracted rates and instead applied its own lower payment methodology. The suit alleged Cigna earned higher 'savings' fees from self-funded plans by paying less than contractually required, leaving patients exposed to balance billing, in breach of its ERISA fiduciary duties.
ProPublica exposes PxDx bulk claim denial system
ProPublica and The Capitol Forum published an investigation revealing that Cigna's PxDx system enabled medical directors to deny over 300,000 claims in a two-month period in 2022, spending an average of 1.2 seconds per case. One medical director denied roughly 60,000 claims in a single month without opening patient files. A corporate document showed Cigna estimated only 5% of people would appeal a PxDx denial.
Cigna CEO orders return to office for most employees
CEO David Cordani sent a companywide email in March 2023 announcing that more employees would be required to work in the office the majority of the time, starting in September 2023 and phased in over time, at a point when about 90% of Cigna employees worked remotely full-time or nearly full-time. Cordani said the goal was on-site attendance closer to pre-pandemic levels.
House committee and regulators launch PxDx scrutiny
The House Energy and Commerce Committee joined state and federal regulators in scrutinizing Cigna's PxDx system after ProPublica's reporting, asking for internal documents on the legality of the review process and on how often PxDx denials were appealed and overturned. Committee chair Rep. Cathy McMorris Rodgers noted that about 80% of appealed prior authorization denials in Cigna's Medicare Advantage plans were overturned. The California Department of Insurance and the accreditors URAC and NCQA also opened reviews.
First PxDx class action lawsuit filed against Cigna
A class action lawsuit was filed in the Eastern District of California alleging Cigna used the PxDx system to batch-deny claims without individually reviewing them, leaving patients with bills the insurer would otherwise have paid. The suit charged that the automated denials violated California's requirement that insurers conduct a 'thorough, fair, and objective' investigation of each claim.
Data breach via Prospect Medical exposes Cigna member information
A ransomware attack on Prospect Medical Holdings in summer 2023 exposed Cigna policyholder information that Cigna had shared with staffing firm Aquent, which passed it to Prospect. Exposed data included names, Social Security numbers, addresses, dates of birth, diagnoses, lab results, medications, treatment and financial information. Prospect did not add Cigna to its list of affected insurers until a January 31, 2024 notice to the Massachusetts attorney general, when it sent notification letters.
Cigna pays $172 million to settle Medicare Advantage upcoding fraud
The Cigna Group agreed to pay $172,294,350 to resolve DOJ False Claims Act allegations that it submitted fraudulent diagnosis codes for Medicare Advantage enrollees between 2012 and 2021. The fraud involved three schemes: the 360 in-home assessment program, a chart review program that added unsubstantiated diagnoses, and inaccurate morbid obesity coding. Cigna entered a five-year Corporate Integrity Agreement with HHS OIG.
Cigna abandons Humana merger, announces $10 billion buyback
After months of negotiations over a potential acquisition of rival Humana that would have created a company valued at over $140 billion, Cigna abandoned the deal because the parties could not agree on price, according to sources. The talks came six years after regulators blocked the Anthem-Cigna and Aetna-Humana mergers. The same day, Cigna announced $10 billion in additional share repurchases, bringing total authorization to $11.3 billion.
Ghost network class action filed against Cigna
Andrew and Andrea Hecht filed an ERISA class action in the Northern District of Illinois alleging inaccuracies in Cigna's online provider directory created a 'ghost network': providers listed as in-network were in fact out-of-network. Members who relied on the directory received thousands of dollars in balance bills; the Hechts said an unpaid hospital balance damaged their credit.
Express Scripts sues FTC over PBM interim report
Express Scripts sued the Federal Trade Commission in the Eastern District of Missouri, calling the agency's July 2024 interim report on pharmacy benefit managers 'unfair, biased, erroneous, and defamatory' and asking a judge to order the report withdrawn and FTC Chair Lina Khan recused from further action against the company.
FTC sues Express Scripts over anticompetitive insulin pricing
The Federal Trade Commission sued Express Scripts, CVS Caremark, and OptumRx for engaging in anticompetitive rebating practices that artificially inflated insulin list prices. The FTC alleged PBMs created a system where manufacturers competed for formulary placement through larger rebates rather than lower net prices. From 1999 to 2017, the average list price of Humalog rose from $21 to over $274 — a 1,200% increase driven in part by the rebate-chasing system.
ProPublica exposes eviCore's adjustable denial 'dial'
A ProPublica and Capitol Forum investigation found that EviCore by Evernorth, Cigna's utilization-management company hired by insurers covering about 100 million people, uses an algorithm insiders call 'the dial' that can be adjusted to send more prior-authorization requests to its doctors for review, raising the chance of denial. Some contracts pay eviCore more the more it cuts spending, and it tells insurers it can deliver a 3-to-1 return on investment.
Cigna prices 2025 health plans with above-normal cost increases
Cigna told analysts that it was pricing 2025 employer health plans on the assumption that medical cost increases would remain higher than normal, according to Cigna Healthcare head Brian Evanko on the company's third-quarter 2024 earnings call. Evanko described the employer market as 'competitive but rational'.
Cigna rules out a Humana merger
After Bloomberg reported in October 2024 that Cigna and Humana had rekindled merger talks, Cigna said it would only consider acquisitions that have a high probability to close, ending on-and-off discussions about combining the companies. It said it would focus on share repurchases in the near term, funded in part by its pending Medicare business sale.
Cigna reports $247 billion revenue with $7 billion in buybacks
The Cigna Group reported full-year 2024 revenues of $247.1 billion, a 27% increase driven primarily by Evernorth Health Services growth. The company repurchased 20.9 million shares for approximately $7 billion and the board authorized an additional $6 billion in repurchase authority, bringing total authorization to $10.3 billion.
Cigna completes $3.7 billion Medicare business sale to HCSC
Cigna completed the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation for $3.7 billion. The divestiture covered nearly 600,000 Medicare Advantage members and 3.6 million total Medicare members. Cigna stated the majority of proceeds would fund share repurchases, while Evernorth continued serving Medicare pharmacy benefits through service agreements.
PxDx class action survives motion to dismiss in federal court
U.S. District Judge Dale Drozd in Sacramento denied in part Cigna's motion to dismiss the PxDx class action. He allowed ERISA breach-of-fiduciary-duty claims to proceed, finding that reading the plan's requirement that a medical director decide medical necessity as allowing an algorithm to decide 'so long as a medical director pushes the button' conflicts with the plan's plain language. California unfair competition claims also advanced, while wrongful-denial-of-benefits claims were dismissed with leave to amend.
Michigan AG files antitrust suit against Express Scripts
The Michigan Attorney General filed an antitrust lawsuit in federal court against Express Scripts and Prime Therapeutics, alleging a conspiracy to fix pharmacy reimbursement rates and drive independent pharmacies out of business. The complaint alleged Express Scripts controlled nearly 90% of Michigan's PBM market and that the conspiracy created pharmacy deserts in half of Detroit's neighborhoods and rural communities.
Express Scripts sues Arkansas to block PBM pharmacy-ownership ban
Express Scripts and its affiliated pharmacies filed a federal lawsuit to strike down Arkansas Act 624, which bars companies that own PBMs from owning pharmacies in the state from January 2026, arguing it violates the Commerce Clause and other constitutional provisions.
MultiPlan algorithmic pricing antitrust claims survive dismissal
U.S. District Judge Matthew Kennelly denied motions to dismiss federal and state antitrust claims in the MultiPlan multidistrict litigation against MultiPlan and insurer defendants including Cigna, Aetna and UnitedHealth, ruling that plaintiffs plausibly alleged that MultiPlan's Data iSight algorithm facilitated a horizontal 'hub-and-spokes' price-fixing agreement among insurers to suppress out-of-network provider reimbursement. The court dismissed only the unjust enrichment claims.
Evernorth invests $3.5 billion in Shields Health Solutions
Cigna's Evernorth invested $3.5 billion in preferred stock of Shields Health Solutions, a specialty pharmacy manager spun out of Walgreens after its sale to Sycamore Partners. The stake is non-controlling but gives Evernorth the option to invest more, extending its reach in specialty pharmacy, a major profit driver for PBMs.
Cigna pauses automatic E/M downcoding policy after physician pushback
Cigna's Reimbursement Policy R49, set to start October 1, 2025, would automatically reduce certain high-level evaluation and management codes by one level without Cigna specifying the algorithms that trigger a downcode. After protests from the American Academy of Sleep Medicine and other medical groups, Cigna agreed to a temporary pause.
Cigna settles ghost network lawsuit for $5.7 million
Cigna agreed to a $5.7 million settlement of the ERISA class action alleging that inaccurate provider directories created a 'ghost network' that misled LocalPlus plan members into believing certain providers were in-network. Under the deal, Cigna will refrain from reprocessing claims, correct the system error, pay up to $300,000 to class members who received balance bills, and cover attorneys' fees and incentive payments. The settlement was awaiting preliminary court approval.
Express Scripts announces move away from rebate model
Evernorth said it would move Express Scripts' commercial clients to a point-of-sale model in which members pay net prices that include negotiated discounts, compensate Express Scripts through fees delinked from drug prices, and reimburse pharmacies on a cost-plus basis. An analyst estimated Cigna already passes through more than 95% of rebate dollars and retained rebates are under 10% of Evernorth's adjusted pre-tax earnings.
Patients sue Accredo, Express Scripts and Cigna over mandatory specialty pharmacy
Patients who must fill specialty prescriptions such as Humira, Revlimid, tacrolimus and multiple sclerosis drugs through Accredo, Express Scripts' in-house specialty pharmacy, filed an antitrust class action against Accredo, Express Scripts and Cigna. They allege Cigna plans list Accredo as the only in-network option for 'specialty' drugs, and that Accredo cancels refills without notice, loses call records, refuses to replace damaged shipments without restarting prior authorization, and sends surprise bills, delaying life-sustaining medication for cancer, MS and organ-transplant patients.
FTC secures landmark settlement with Express Scripts
The FTC settled its insulin-pricing case against Express Scripts with a proposed consent order. Express Scripts agreed to stop preferring high-list-price versions of drugs over identical low-price versions on standard formularies, base members' out-of-pocket costs on net rather than list prices in a standard offering, delink manufacturer compensation from list prices, offer plan sponsors a standard option free of rebate guarantees and spread pricing, move community pharmacy reimbursement to acquisition cost plus a dispensing fee, increase drug-level transparency reporting, and reshore its Ascent GPO. The FTC projected up to $7 billion in patient out-of-pocket savings over 10 years.
Cigna reports $274.9 billion 2025 revenue and $3.6 billion of buybacks
The Cigna Group reported 2025 revenue of $274.9 billion, up 11%, and shareholders' net income of $6.0 billion. It repurchased 11.9 million shares for about $3.6 billion in 2025, down from about $7 billion in 2024, and raised its quarterly dividend to $1.56 per share.
Cigna announces 2,000-employee global workforce reduction
Cigna said it would eliminate approximately 2,000 roles globally, less than 3% of its workforce, by the end of February 2026, citing a drive for greater efficiency. The company did not say which units or roles would be affected. The cuts are part of an operational streamlining initiative Cigna began in early 2025.
Union health fund files RICO class action against Express Scripts and Cigna
Plumbers' Welfare Fund, Local 130 filed a class action in the Northern District of Illinois against Express Scripts and its parents Cigna and Evernorth on behalf of Express Scripts' PBM customers, alleging a racketeering scheme that diverted billions of dollars in drug-maker payments to an offshore entity and sold manufacturers favorable formulary placement.
Cigna names Brian Evanko to succeed CEO David Cordani
The Cigna Group said David Cordani would retire as CEO effective July 1, 2026, after nearly 17 years, and become executive chair of the board, with president and COO Brian Evanko, a nearly 30-year company veteran, succeeding him.
Maryland fines Cigna $80,000 over automatic downcoding
The Maryland Insurance Administration fined Cigna $80,000 and required it to stop automatically downcoding evaluation and management claims under its policy, finding the practice not allowed under state law and identifying payment delays. Cigna must instead formally dispute claims it believes are improper and request documentation. Cigna said the policy affects about 1% of in-network physicians.
Court grants final approval to $5.7 million ghost-network settlement
A federal judge in Illinois gave final approval to Cigna's $5.7 million settlement of the Hecht ERISA class action alleging that Cigna advertised out-of-network providers as in-network.
Cigna joins prior-authorization standardization pledge, cites 15% volume cut
The Cigna Group joined other health plans in committing to standardize electronic prior-authorization submission requirements, expecting the standard to cover services representing more than 70% of its prior-authorization volume by the end of 2026. It said it had already reduced overall medical prior-authorization volume by about 15%.
Cigna to exit ACA exchanges and explore sale of eviCore
Reporting a 25% rise in first-quarter profit to $1.7 billion, Cigna said it would leave the ACA exchanges after 2026, leaving about 369,000 members in 11 states to find new coverage, because it saw no path to scale the shrinking business. It also began exploring strategic alternatives for eviCore, its prior-authorization review subsidiary.
Express Scripts sues Tennessee to block PBM pharmacy-ownership law
Express Scripts filed a federal lawsuit challenging Tennessee's FAIR Rx Act, which bars PBMs from owning pharmacies in the state from 2028, arguing it is unconstitutional and preempted by ERISA and TRICARE. Cigna said the law would force it to close a Memphis dispensing facility that ships drugs to nearly half a million patients nationwide.
Premium rate increases lift Cigna's second-quarter results
The Cigna Group reported second-quarter 2026 revenue of $71.7 billion, up 7%, and net income of $1.7 billion, primarily reflecting growth in Cigna Healthcare, whose adjusted revenue rose on premium rate increases to cover expected medical cost increases. It raised its 2026 outlook and had repurchased about $250 million of stock year to date through July 29.
Florida attorney general sues Express Scripts and Prime over price fixing
Florida Attorney General James Uthmeier sued Express Scripts and Prime Therapeutics in state court, alleging their 2019 arrangement letting Prime adopt Express Scripts' lower pharmacy reimbursement rates was horizontal price fixing. The complaint says reimbursement on some drugs fell by as much as 80% for certain Florida pharmacies.
Louisiana attorney general sues Express Scripts over drug pricing
Louisiana Attorney General Liz Murrill sued Express Scripts and its affiliate Ascent Health Services, accusing them of using market power to manipulate pharmacy reimbursement, conceal profits and steer patients to pharmacies they own or control, and of coordinating reimbursement with Prime Therapeutics. The state seeks damages, civil penalties and an injunction.
Evidence (63 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (9 entries)
[Second regrade this cycle] 64->64, no dimension or era score moved. Follow-up after restore-check; no new research (window since the 2026-09-26 regrade is one day). Restored facts re-checked against their sources and weighed against the criteria: (1) 2015-04-30 Accredo $60M Exjade kickback settlement (DOJ SDNY) - did not move D10 or D2 in 'PxDx and Medicare Push' (2010-01-01): Accredo belonged to the then-independent Express Scripts, not Cigna, so it is not this product's conduct in that era; Cigna's own record there (2013 multistate disability settlement, 2012-14 MA upcoding programs, 2016 CMS sanctions) already fits D10 5, and D2 4 rests on Cigna's own provider-side conduct. It also did not move D10 5 in 'PBM Vertical Integration' (2018-12-20): a settlement concluded before the acquisition says nothing about Cigna's regulatory posture after it. Added to that era's summary as context for what Cigna absorbed. (2) 2014 Express Scripts layoffs (1,890 in May + 400 in Nov, STLPR) - did not move D9 3 in the 2010 era: they were Express Scripts' workforce decisions four years before Cigna owned it, and they came as its revenue fell about 5%, not during record profits. (3) Lawmakers' 60% mail-order share warning for ESI-Medco (PharmaTimes, attributed) - did not move D8: the 2010-era D8 4 is Cigna's own HealthSpring buy and the blocked Anthem deal, and the 2018-era D8 6 already reflects Cigna absorbing the Medco-enlarged PBM (Brill's 45% share figure was already in the record); an attributed pre-merger warning adds no new direction. Eras: all 6 kept with dates, labels and scores unchanged; 'PBM Vertical Integration' summary revised to name the Medco merger and the 2015 Accredo settlement as part of what Cigna absorbed.
Checked 89 items + prose. 28 verified, 39 corrected (11 date-only), 17 re-sourced, 5 removed (1 junk-sourced/unfindable, 2 unverifiable Glassdoor, 1 unsupported placeholder, 1 bogus IPO milestone). Invented: prior-authorization '8-12 hours weekly / 25-40 minutes each' stats in D6 narrative. Major fixes: 2,000-job cut redated 2024->2026; FTC settlement terms overstated; wrong judge (Mueller->Drozd) in PxDx ruling; MultiPlan ruling redated 2024->2025; 80% overturn misattributed to PxDx; Anthem bid $47B->$54.2B; $77M disability 'fund' was a charge; ghost-network settlement not yet approved; Prospect breach misattributed to a different Top Class Actions breach.
64->64. Since Feb 2026: FTC-Express Scripts proposed consent order (Feb 4), ~2,000 job cuts, RICO class action, CEO succession (Evanko CEO Jul 1), Maryland $80K downcoding fine, ghost-network settlement approved, PA volume cut ~15%, ACA exchange exit and eviCore review, Express Scripts suit vs Tennessee, Florida and Louisiana AG price-fixing suits; buybacks slowed to ~$250M YTD. D1 7->6 (event: PA volume cut, Medicare Advantage sold so the 80% overturn data no longer applies, top J.D. Power digital ranking); D3 7->6 (event: buybacks fell from ~$7B in 2024 to $3.6B in 2025 and ~$250M through Jul 2026); D4 6->5 (recalibration: barriers are mostly category-wide employer-choice constraints; Cigna-specific Accredo exclusivity and ghost network fit 4-5, not 6-7); D7 5->6 (recalibration: insurer+PBM+specialty pharmacy+eviCore margin capture on the same member fits the top of the guide's medium band; reforms not yet in effect); D9 6->7 (event: gap-filled ProPublica 2024 reporting on medical-director productivity quotas and firing threat, plus layoffs during record revenue); D10 6->7 (event: Express Scripts suits against FTC, Arkansas and Tennessee to block regulation; Maryland fine; 2016 CMS sanctions gap-filled). Trajectory worsening->stable (reforms and PA cuts offset new suits and layoffs). Eras: all 6 re-dated: formation 1982-03-01->1982-03-31; 'Managed Care Maturation' 2000-01-01->1999-07-02 (ACE P&C sale) relabeled 'Health Benefits Pivot'; 'Industry Consolidation Wave' 2012-04-01->2010-01-01 (PxDx built) relabeled 'PxDx and Medicare Push'; 'PBM Vertical Integration' 2019-01-01->2018-12-20 (Express Scripts close); 'PxDx Scandal Erupts' 2023-03-01->2023-03-25 (ProPublica); current era 2026-02-16 (assessment date)->2026-02-04 (FTC settlement) relabeled 'Settlement and Retrenchment'. Earlier eras rescored higher after gap-fills (2002 IT meltdown, 2003 physician settlement, 2007 Sarkisyan, 2016 CMS sanctions, 2020 medical-director quotas).
Checked 2 alternatives. Removed Traditional Medicare + Medigap: it targeted Cigna Medicare Advantage members, a business Cigna sold to HCSC in 2025. Kaiser: replaced unsourced denial/satisfaction claims with sourced figures (6% vs 21% denial rate; J.D. Power 2024 regional wins), softened 'structurally absent' overclaim, added the 2023 $200M California mental-health access settlement as caveat, and tied it to Cigna's ACA exchange exit. No second replacement added: employer-sponsored members rarely choose their insurer, and no other plan was verified as clearly better nationally.
Checked 16 removed/trimmed claims: 1 restored, 3 partly restored, 11 confirmed removed, 1 already present. Restored (added): 2015-04-30 Accredo $60M Exjade kickback settlement (RESTORED, DOJ SDNY release); 2014-11-05 Express Scripts layoffs of 1,890 + 400 jobs with professor linking some to Medco streamlining (PARTLY RESTORED from the 2016 post-Medco layoff item, St. Louis Public Radio; Columbus site and $600M synergies still unsupported). Partly restored: 60% mail-order share as lawmakers' claim (PharmaTimes); Cordani 2021 proxy figure $19.9M (Fierce Healthcare). Confirmed removed: 2008 rebate characterization, 2023 14% cut, seven consecutive months of layoffs, 82,000-jobs comparison, RTO 50-mile/offer-letter details (forums only), $4.2B CG-INA value, 10%+ premium context, ACA 10-15% hikes, PxDx per-month figure, ghost-network preliminary approval at Oct 2025 (final approval already recorded). Already present: Travelers ERISA description.
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).